摘要
目的:探讨谷胱甘肽转移酶(GST-π)和肺耐药蛋白(LRP)在胃癌中的表达及其临床意义。方法:应用免疫组化法检测GST-π和LRP在80例胃癌组织和20例正常胃粘膜组织中的表达,探讨胃癌组织学类型、肿瘤浸润深度及有无淋巴结转移对GST-π和LRP表达的影响。结果:GST-π和LRP在胃癌组织中的阳性表达率高于正常胃粘膜组织(P<0.05);在高中分化腺癌中的表达显著高于低分化腺癌(P<0.05);在浸润粘膜及粘膜下层组、肌层组、浆膜及浆膜外组表达率无显著差别(P>0.05);在有淋巴结转移组GST-π、LRP表达率显著高于无淋巴结转移组(P<0.05)。结论:GST-π、LRP在胃癌原发性多药耐药中起重要作用,其表达与组织学类型、有无淋巴结转移有关,而与肿瘤浸润深度无关,联合检测GST-π、LRP对于胃癌判断预后、制定化疗方案有一定的指导意义。
Objective: To study the clinical significance and expression of glutathione-s-trannsferase(GST-π) and lung resistance protein(LRP) in gastric carcinoma tissue.Method: The expression of GST-πand LRP in 80 cases of Gastric carcinoma and 20 cases of normal stomach tissues were detected by immunohistochemical technique,its correlation with clinical pathologic characteristic of gastric carcinoma,including histological type,invasion degree and lymph node metastasis,were explored.Result: The positive expression rates of GST-π and LRP in gastric carcinoma were all higher than those in normal stomach tissues(P〈0.05).The expression rates of GST-π and LRP in well-moderated differentiated adenocarcinoma were significantly higher than those in poor differentiated adenocarcinoma(P〈0.05).There was no significant difference between the expression rates of GST-π and LRP in the three groups which invading mucoma and submocuma,invading musculairs and invading serosa and beyond serosa(P〉0.05).The expression rates of GST-π and LRP in tissues with lymph metastasis were significantly higher than in those without lymph node metastasis(P〈0.05).Conclusion: GST-π and LRP play important roles in the primary multidrug resistance(MDR)of gastric carcinoma.The expression of them is associated with histological type and lymph node metaaastasis,while not associated with invased layer.The determination of GST-πand LRP may be useful for the estimatation of prognosis and the establishment of chemical therapy regimen in gastric carcinoma.
出处
《河北医学》
CAS
2007年第7期766-769,共4页
Hebei Medicine
关键词
胃癌
谷胱甘肽S转移酶
肺耐药蛋白
多药耐药
Gastric carcinoma
Glutathione-s-trannsferase(GST-π)
Lung resistance protein(LRP)
Multidrug resistance(MDR)